论文部分内容阅读
分子生物学的深入探讨使自然杀伤细胞(natural killer cell,NK cell)在肿瘤发生发展过程中的作用重新被人们所认识;NK细胞的扩增作为免疫治疗的手段又开始受到人们的重视。以往,虽然证明NK细胞的过继免疫治疗是安全的,但自体NK细胞过继免疫治疗的临床疗效却不能令人满意。新近的研究发现,通过靶向药物单克隆抗体的协同,可以明显改善其抗肿瘤效果。对NK细胞表面受体的研究证明抑制性受体KIR在逃避免疫中起了重要作用,而抑制这些受体能够明显提高NK细胞的杀伤效率,为临床应用提供了可靠的理论基础和实际应用的可行性。异体半相合NK细胞的临床应用有可能克服自身NK细胞的缺陷,而对细胞信号进行靶向调节是最重要的突破,将进一步为临床广泛应用提供了可能。本文就NK细胞过继免疫治疗的最新进展作一综述。
The further exploration of molecular biology has re-established the role of natural killer cell (NK cell) in the process of tumorigenesis. The expansion of NK cell has begun to receive more and more attentions as a means of immunotherapy. In the past, although adoptive immunotherapy of NK cells proved to be safe, the clinical efficacy of adoptive immunotherapy with autologous NK cells was unsatisfactory. Recent studies have shown that antitumor effects can be significantly improved by synergistic targeting of drug monoclonal antibodies. Studies on NK cell surface receptors have demonstrated that KIR, an inhibitory receptor, plays an important role in immune evasion and inhibition of these receptors can significantly increase the killing efficiency of NK cells, providing a reliable theoretical basis and practical application for clinical application feasibility. The clinical application of allogeneic haploidentical NK cells is likely to overcome the defects of its own NK cells, and targeted regulation of cell signaling is the most important breakthrough, which will further make it possible for clinical application. This article reviews the latest progress of adoptive immunotherapy of NK cells.